Black Diamond Therapeutics, Inc. BDTX
At closeNov 10, 2026, 4:12 PM EST
After hours · Nov 10, 4:12 PM ET
- YTD
- -34.36%
- 1 year
- -63.42%
- Market cap
- 91.40M
- EPS (ttm)
- -0.75
- Shares out
- 56.59M
- Forward P/E
- -1.80
- YTD return
- -34.36%
- 1-year return
- -63.42%
- Volume
- 1.38M
- Avg volume
- 674.96K
- Open
- 1.90
- Previous close
- 1.86
- Day's range
- 1.58 – 1.91
- 52-week range
- 1.58 – 4.94
- Beta
- 2.52
- Price target
- 14.50 (+809.1%)
- Earnings date
- Aug 6, 2024
5D -0.24 (-12.44%)
Key statistics
- Enterprise value
- 35.94M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 1.27
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -34.59M
- Total cash
- 112.68M
- Total debt
- 23.00M
- Return on equity
- -63.09%
- Short % of float
- 18.22%
- 50-day average
- 2.79
- 200-day average
- 4.63
Analyst view
- Target (low)
- 9.00
- Target (mean)
- 14.50
- Target (high)
- 20.00
- Strong buy3
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 6, 2024
Expected Aug 6, 2024. Consensus EPS estimate -0.31167.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2024 | Sep 1, 2024 | -0.37 | -0.28 | +0.09 | +24.32% |
| Aug 6, 2024 | Jun 1, 2024 | -0.39 | -0.36 | +0.03 | +7.69% |
| Aug 6, 2024 | Jun 1, 2024 | -0.39 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -0.44 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -0.44 | -0.35 | +0.09 | +20.45% |
| Mar 12, 2024 | Dec 1, 2023 | -0.47 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 6, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 9, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 8, 2024 | Wedbush | reit | Outperform | Outperform |
| Sep 24, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 23, 2024 | Piper Sandler | main | Overweight | Overweight |
| Sep 18, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- blackdiamondtherapeutics.com
News
Why Is Black Diamond Therapeutics Stock Soaring Tuesday? 
Why Is Black Diamond Therapeutics Stock Soaring Tuesday? 
Black Diamond Therapeutics, Inc. (BDTX) Discusses Silevertinib Phase II Data and Phase III Development Plans Transcript 
Black Diamond Therapeutics Reports Updated Phase 2 Silevertinib Data, FDA End-Of-Phase 2 Feedback, Supporting Pivotal Development In All 1L EGFR-NCM NSCLC Patients With Potential For Accelerated Approval Based On CNS-ORR 
Black Diamond Therapeutics Announces Positive Updated Silevertinib Phase 2 Results, FDA Feedback Supporting a Clear Path to Potential Registration in 1L EGFR-NCM NSCLC, and Provides Corporate Update 
Black Diamond Therapeutics To Host A Webcast For Investors To Present Updated Results From Its Ongoing Phase 2 Trial Of Silevertinib 
Black Diamond Therapeutics: Delay In Trial Results Leads To A Downgrade, But It's Still A Buy 
HC Wainwright & Co. Reiterates Buy on Black Diamond Therapeutic, Maintains $11 Price Target 
Black Diamond Therapeutic Q2 EPS $(0.17) Beats $(0.19) Estimate 
What's Going On With Black Diamond Therapeutics Stock Tuesday?
Your note
Sign in to keep a note on BDTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BEHBAHANI ALI | Director | Stock Award(Grant) | Dec 12, 2024 | 4,512,090 |
| BIOTECH GROWTH N.V. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Oct 16, 2023 | 0 |
| CAMPBELL SHANNON | Director | Stock Award(Grant) | Dec 12, 2024 | 8,865 |
| DIXON WENDY L | Director | Stock Award(Grant) | Mar 14, 2024 | 38,054 |
| EPSTEIN DAVID M | Chief Executive Officer | Sale | Jun 26, 2023 | 936,569 |
| JONES ERIKA | Officer | Stock Award(Grant) | Feb 12, 2023 | 10,150 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 18.97% | 10,734,389 | 23.51M | Sep 29, 2024 |
| Bellevue Group AG | 15.05% | 8,517,839 | 18.65M | Sep 29, 2024 |
| Vestal Point Capital, LP | 8.89% | 5,028,500 | 11.01M | Sep 29, 2024 |
| NEA Management Company, LLC | 7.86% | 4,448,757 | 9.74M | Sep 29, 2024 |
| Blackrock Inc. | 6.18% | 3,497,766 | 7.66M | Sep 29, 2024 |
| Vanguard Group Inc | 4.10% | 2,318,011 | 5.08M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Price (T.Rowe) Small-Cap Value Fund | 4.53% | 2,560,552 | 5.61M | Sep 29, 2024 |
| Price (T.Rowe) Small Cap Stock Fund | 4.43% | 2,508,412 | 5.49M | Sep 29, 2024 |
| Vanguard Total Stock Market Index Fund | 2.35% | 1,329,831 | 2.91M | Sep 29, 2024 |
| Price (T.Rowe) Institutional Small-Cap Stock Fund | 2.18% | 1,236,268 | 2.71M | Sep 29, 2024 |
| Price (T.Rowe) U.S. Small-Cap Value Equity Trust | 2.18% | 1,234,985 | 2.70M | Sep 29, 2024 |
| Price (T.Rowe) U.S. Small-Cap Core Equity Trust | 2.13% | 1,208,091 | 2.65M | Sep 29, 2024 |